Ginkgo Bioworks Q1 revenue $19M (-49% YoY); narrows net loss; cash burn guidance reaffirmed

Ginkgo Bioworks Holdings, Inc.

Revenue $19M, down 49% YoY; prior year included $7M non-cash deferred revenue release; adjusted EBITDA -$42M.
GAAP net loss from continuing ops -$76M (vs -$83M prior year); operating cash burn trajectory reaffirmed.
Completed Biosecurity divestiture on April 3, 2026; results presented as discontinued ops.
Cash, cash equivalents and marketable securities $373M as of March 31, 2026.
Reaffirms FY 2026 total cash burn guidance of $(150)-$(125) million.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.